SEATTLE — July 9, 2019 — Fred Hutchinson Cancer Research Center announced the addition of two new members to its board of trustees. Dr. Corsee Sanders, a strategic adviser to the office of the Chief Medical Officer at Celgene Corporation and Sean Boyle, chief financial officer for Amazon Web Services, or AWS, officially began their board service in June.
Sanders has over 25 years of drug development experience in her leadership roles at Juno Therapeutics (which was acquired by Celgene Corporation in the first quarter of 2018), Genentech and Roche Pharmaceuticals. With expertise in quantitative sciences, clinical and development operations, as well as industry collaborations, Sanders has played a critical role bringing innovative cancer therapies from the bench to patients.
Boyle brings over 25 years of expertise in finance and technology to the board. He’s served as the chief financial officer for AWS since 2015 and has helped the technology company become one of the world’s most comprehensive and broadly adopted cloud platforms.
“Sean and Corsee are two of the most strategic, intelligent and hard-working people I know,” said Matt McIlwain, managing director at Madrona Venture Group and chair of the Fred Hutch board. “We’re fortunate to have the best minds in technology, science and innovation in Seattle, working together to drive cancer research. The experience that Sean and Corsee bring will only accelerate our efforts.”
Sanders joined the board to share her expertise in bringing therapies to patients and helping bridge the gap between academic research and the pharmaceutical and biotech industries.
“I’ve always been fascinated by the groundbreaking work done at renowned research organizations like Fred Hutch,” said Sanders. “Being able to contribute to the discovery and the nurturing of a future for cancer patients is a special opportunity to make a difference in the fight against this disease.”
Boyle’s interest in Fred Hutch stems from his passion to give back to the community and find new ways to reduce the negative health and financial impacts of cancer treatments.
“Cancer has affected far too many people including many of my closest friends and family members,” said Boyle. “The amazing work that Fred Hutch is doing to not only find cures, but to mitigate or eliminate toxicities of all types, is incredibly meaningful. I’m honored to be a part of a team working to solve such important problems facing patients.”
“We are honored to welcome Sean and Corsee to the Fred Hutch family,” said Dr. Gary Gilliland, president and director of Fred Hutch. “The board plays a valuable role in shaping our strategies and Sean’s expertise in technology and finance combined with Dr. Sanders’ experience with clinical trials and drug development will help us reach our goal of finding curative approaches for cancers by 2025.”
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network.